Gregory J. Kato

List of Publications by Year
in descending order

326	14,521	16411	22102
papers	citations	h-index	g-index

338	338	338	10674
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sickle cell disease. Nature Reviews Disease Primers, 2018, 4, 18010.	18.1	764
2	Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews, 2007, 21, 37-47.	2.8	728
3	Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2005, 294, 81.	3.8	619
4	Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 2006, 107, 2279-2285.	0.6	561
5	Intravascular hemolysis and the pathophysiology of sickle cell disease. Journal of Clinical Investigation, 2017, 127, 750-760.	3.9	435
6	An amino-terminal c-myc domain required for neoplastic transformation activates transcription.. Molecular and Cellular Biology, 1990, 10, 5914-5920.	1.1	410
7	Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood, 2007, 110, 2166-2172.	0.6	316
8	Max: functional domains and interaction with c-Myc.. Genes and Development, 1992, 6, 81-92.	2.7	266
9	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease. Journal of the American College of Cardiology, 2007, 49, 472-479.	1.2	265
10	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 2011, 118, 855-864.	0.6	210
11	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	2.5	197
12	Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis. JAMA - Journal of the American Medical Association, 2011, 305, 893.	3.8	196
13	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British Journal of Haematology, 2005, 130, 445-453.	1.2	192
14	Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology, 2005, 130, 943-953.	1.2	188
15	Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 599-602.	3.3	179
16	Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension. JAMA - Journal of the American Medical Association, 2012, 307, 1254.	3.8	179
17	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica, 2013, 98, 464-472.	1.7	170
18	N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2006, 296, 310.	3.8	169

#	Article	IF	Citations
19	Intracellular leucine zipper interactions suggest c-Myc hetero-oligomerization.. Molecular and Cellular Biology, 1991, 11, 954-962.	1.1	166
20	Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica, 2009, 94, 340-347.	1.7	164
21	A network model to predict the risk of death in sickle cell disease. Blood, 2007, 110, 2727-2735.	0.6	159
22	Function of the câ€Myc oncoprotein. FASEB Journal, 1992, 6, 3065-3072.	0.2	155
23	Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain. PLoS ONE, 2008, 3, e2095.	1.1	152
24	Mechanisms of hemolysisâ€associated platelet activation. Journal of Thrombosis and Haemostasis, 2013, 11, 2148-2154.	1.9	144
25	Pulmonary Complications of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1154-1165.	2.5	143
26	Amplified Expression Profiling of Platelet Transcriptome Reveals Changes in Arginine Metabolic Pathways in Patients With Sickle Cell Disease. Circulation, 2007, 115, 1551-1562.	1.6	126
27	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124
28	Sickle cell disease and nitric oxide: A paradigm shift?. International Journal of Biochemistry and Cell Biology, 2006, 38, 1237-1243.	1.2	121
29	Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 840-847.	2.5	114
30	Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. Journal of Clinical Investigation, 2014, 124, 2750-2761.	3.9	112
31	Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. British Journal of Haematology, 2007, 136, 319-325.	1.2	109
32	Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. American Journal of Hematology, 2008, 83, 15-18.	2.0	108
33	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	1.1	107
34	Circulating Blood Endothelial Nitric Oxide Synthase Contributes to the Regulation of Systemic Blood Pressure and Nitrite Homeostasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1861-1871.	1.1	105
35	Current therapy of sickle cell disease. Haematologica, 2006, 91, 7-10.	1.7	102
36	Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1422-1427.	3.3	99

#	Article	IF	Citations
37	Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatric Blood and Cancer, 2008, 50, 1006-1012.	0.8	97
38	Hemolysis-Associated Pulmonary Hypertension in Thalassemia. Annals of the New York Academy of Sciences, 2005, 1054, 481-485.	1.8	96
39	Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders. Current Molecular Medicine, 2008, 8, 620-632.	0.6	95
40	Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight, 2017, 2, e89761.	2.3	95
41	Cardiopulmonary Complications of Sickle Cell Disease: Role of Nitric Oxide and Hemolytic Anemia. Hematology American Society of Hematology Education Program, 2005, 2005, 51-57.	0.9	93
42	PULMONARY HYPERTENSION IN SICKLE CELL DISEASE: Relevance to Children. Pediatric Hematology and Oncology, 2007, 24, 159-170.	0.3	93
43	Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. American Journal of Hematology, 2008, 83, 485-490.	2.0	93
44	Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management. American Journal of Hematology, 2008, 83, 63-70.	2.0	91
45	Severe Painful Vaso-Occlusive Crises and Mortality in a Contemporary Adult Sickle Cell Anemia Cohort Study. PLoS ONE, 2013, 8, e79923.	1.1	91
46	Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology, 2006, 81, 503-510.	2.0	90
47	Pulmonary Hypertension in Children and Adolescents with Sickle Cell Disease. Pediatric Cardiology, 2008, 29, 309-312.	0.6	89
48	Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. British Journal of Haematology, 2009, 145, 506-513.	1.2	85
49	Markers of Severe Vaso-Occlusive Painful Episode Frequency in Children and Adolescents with Sickle Cell Anemia. Journal of Pediatrics, 2012, 160, 286-290.	0.9	84
50	Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21WAF1/CIP1 proteins in human acute lymphoblastic leukemia cells. Blood, 2002, 99, 3390-3397.	0.6	79
51	Sleep disturbance, depression and pain in adults with sickle cell disease. BMC Psychiatry, 2014, 14, 207.	1.1	78
52	Clinical Outcomes Associated With Sickle Cell Trait. Annals of Internal Medicine, 2018, 169, 619.	2.0	78
53	Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells.. Molecular and Cellular Biology, 1992, 12, 3130-3137.	1.1	77
54	High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood, 2010, 116, 109-112.	0.6	77

#	Article	IF	Citations
55	Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy. JAMA - Journal of the American Medical Association, 2008, 300, 2638.	3.8	74
56	Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood, 2012, 120, 1961-1962.	0.6	73
57	Framing the research agenda for sickle cell trait: Building on the current understanding of clinical events and their potential implications. American Journal of Hematology, 2012, 87, 340-346.	2.0	72
58	Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica, 2011, 96, 33-40.	1.7	71
59	A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. BMC Medical Genomics, 2012, 5, 28.	0.7	71
60	Iron, Inflammation, and Early Death in Adults With Sickle Cell Disease. Circulation Research, 2015, 116, 298-306.	2.0	71
61	Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood, 2009, 113, 1122-1128.	0.6	70
62	Lipid levels in sickleâ€cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. British Journal of Haematology, 2010, 149, 436-445.	1.2	70
63	Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. British Journal of Haematology, 2009, 147, 737-743.	1.2	69
64	Plasma thrombospondinâ€1 is increased during acute sickle cell vasoâ€occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. American Journal of Hematology, 2012, 87, 326-330.	2.0	68
65	Platelet Extracellular Vesicles Drive Inflammasomeâ€“IL-1Î²â€“Dependent Lung Injury in Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 33-46.	2.5	66
66	Therapeutic Strategies to Alter the Oxygen Affinity of Sickle Hemoglobin. Hematology/Oncology Clinics of North America, 2014, 28, 217-231.	0.9	65
67	Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood, 2009, 114, 4639-4644.	0.6	62
68	Pleiotropic effects of intravascular haemolysis on vascular homeostasis. British Journal of Haematology, 2010, 148, 690-701.	1.2	62
69	Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. American Journal of Hematology, 2014, 89, 1-6.	2.0	62
70	Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!. Haematologica, 2008, 93, 1-3.	1.7	61
71	Angiogenic and Inflammatory Markers of Cardiopulmonary Changes in Children and Adolescents with Sickle Cell Disease. PLoS ONE, 2009, 4, e7956.	1.1	61
72	E2A Basic-Helix-Loop-Helix Transcription Factors are Negatively Regulated by Serum Growth Factors and by the Id3 Protein. Nucleic Acids Research, 1996, 24, 2813-2820.	6.5	60

#	Article	IF	Citations
73	Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. American Journal of Hematology, 2008, 83, 6-14.	2.0	60
74	Imaging flow cytometry for automated detection of hypoxiaâ€induced erythrocyte shape change in sickle cell disease. American Journal of Hematology, 2014, 89, 598-603.	2.0	60
75	Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. British Journal of Haematology, 2008, 142, 971-978.	1.2	59
76	Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients. British Journal of Haematology, 2009, 147, 352-359.	1.2	59
77	Pulmonary hypertension and NO in sickle cell. Blood, 2010, 116, 852-854.	0.6	59
78	Hematologic, biochemical, and cardiopulmonary effects of <scp>l</scp>â€arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. European Journal of Haematology, 2009, 82, 315-321.	1.1	58
79	New developments in antiâ€sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin inÂvivo?. British Journal of Haematology, 2016, 175, 24-30.	1.2	58
80	Prospective Echocardiography Assessment of Pulmonary Hypertension and Its Potential Etiologies in Children With Sickle Cell Diseaseâ€â€Conflicts of interest: Dr. Gordeuk has received grants from BioMarin Pharmaceutical Inc., Novato, California, and Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, and is a consultant for Ikaria Holdings, Clinton, New Jersey.. American Journal of Cardiology, 2009, 104, 713-720.	0.7	56
81	Critical Reviews: How we treat sickle cell patients with leg ulcers. American Journal of Hematology, 2016, 91, 22-30.	2.0	56
82	Leg Ulcers in Sickle Cell Disease: Current Patterns and Practices. Hemoglobin, 2013, 37, 325-332.	0.4	55
83	Simultaneous polymerization and adhesion under hypoxia in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9473-9478.	3.3	55
84	NTâ€pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. British Journal of Haematology, 2011, 154, 512-520.	1.2	51
85	Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. British Journal of Haematology, 2008, 141, 254-259.	1.2	49
86	Diastolic dysfunction in sickle cell. Blood, 2010, 116, 1-2.	0.6	48
87	Hydroxyurea-Induced Expression of Glutathione Peroxidase 1 in Red Blood Cells of Individuals with Sickle Cell Anemia. Antioxidants and Redox Signaling, 2010, 13, 1-11.	2.5	47
88	Dietâ€induced Weight Loss in Overweight or Obese Women and Changes in Highâ€Density Lipoprotein Levels and Function. Obesity, 2012, 20, 2057-2062.	1.5	45
89	Genetic determinants of haemolysis in sickle cell anaemia. British Journal of Haematology, 2013, 161, 270-278.	1.2	45
90	Extensive Ex Vivo Expansion of Functional Human Erythroid Precursors Established From Umbilical Cord Blood Cells by Defined Factors. Molecular Therapy, 2014, 22, 451-463.	3.7	45

#	Article	IF	Citations
91	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica, 2006, 91, 1076-83.	1.7	45
92	Increased Pulmonary Pressures and Myocardial Wall Stress in Children with Severe Malaria. Journal of Infectious Diseases, 2010, 202, 791-800.	1.9	44
93	Abnormal Pulmonary Function and Associated Risk Factors in Children and Adolescents With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2014, 36, 185-189.	0.3	44
94	Liver injury is associated with mortality in sickle cell disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 912-921.	1.9	44
95	Haptoglobin halts hemoglobinâ€™s havoc. Journal of Clinical Investigation, 2009, 119, 2140-2.	3.9	44
96	Laboratory and echocardiography markers in sickle cell patients with leg ulcers. American Journal of Hematology, 2011, 86, 705-708.	2.0	42
97	Heme-bound iron activates placenta growth factor in erythroid cells via erythroid KrÃ¼ppel-like factor. Blood, 2014, 124, 946-954.	0.6	40
98	A Novel Molecular Signature for Elevated Tricuspid Regurgitation Velocity in Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 359-368.	2.5	39
99	The Worst Things in Life are Free: The Role of Free Heme in Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 561917.	2.2	39
100	A GCH1 haplotype confers sexâ€specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia. American Journal of Hematology, 2014, 89, 187-193.	2.0	38
101	Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. American Journal of Hematology, 2009, 84, 529-531.	2.0	37
102	A Retrospective Review of Acupuncture Use for the Treatment of Pain in Sickle Cell Disease Patients. Clinical Journal of Pain, 2014, 30, 825-830.	0.8	37
103	Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. Lancet Haematology,the, 2014, 1, e95-e103.	2.2	37
104	High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood, 1993, 82, 2304-2309.	0.6	36
105	Human genetic diseases of proteolysis. Human Mutation, 1999, 13, 87-98.	1.1	36
106	Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9527-9532.	3.3	36
107	Ancestry of African Americans with sickle cell disease. Blood Cells, Molecules, and Diseases, 2011, 47, 41-45.	0.6	35
108	Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica, 2013, 98, e132-e134.	1.7	35

#	Article	IF	Citations
109	Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. Haematologica, 2014, 99, e214-e217.	1.7	34
110	Priapism in Sickle-Cell Disease: A Hematologistâ€™s Perspective. Journal of Sexual Medicine, 2012, 9, 70-78.	0.3	33
111	Imaging flow cytometry for morphologic and phenotypic characterization of rare circulating endothelial cells. Cytometry Part B - Clinical Cytometry, 2013, 84, 379-389.	0.7	33
112	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	1.5	33
113	Association of G6PD^{202A,376G} with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. British Journal of Haematology, 2010, 150, 218-225.	1.2	31
114	Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension. Medical Physics, 2010, 37, 1522-1532.	1.6	30
115	Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. European Journal of Haematology, 2013, 91, 62-68.	1.1	30
116	New insights into sickle cell disease. Current Opinion in Hematology, 2016, 23, 224-232.	1.2	30
117	Homozygous factor-V mutation as a genetic cause of perinatal thrombosis and cerebral palsy. Developmental Medicine and Child Neurology, 1999, 41, 777-780.	1.1	30
118	Successful Treatment of Life-Threatening Acute Chest Syndrome of Sickle Cell Disease with Venovenous Extracorporeal Membrane Oxygenation. Journal of Pediatric Hematology/Oncology, 1997, 19, 459-461.	0.3	29
119	Identification and characterization of the novel centrosome-associated protein CCCAP. Gene, 2003, 303, 35-46.	1.0	27
120	Near-infrared spectra absorbance of blood from sickle cell patients and normal individuals. Hematology, 2009, 14, 46-48.	0.7	27
121	Pulmonary artery pressure and iron deficiency in patients with upregulation of hypoxia sensing due to homozygous VHLR200W mutation (Chuvash polycythemia). Haematologica, 2012, 97, 193-200.	1.7	26
122	Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. Haematologica, 2013, 98, 455-463.	1.7	26
123	Elevated Pulse Pressure is Associated with Hemolysis, Proteinuria and Chronic Kidney Disease in Sickle Cell Disease. PLoS ONE, 2014, 9, e114309.	1.1	26
124	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	3.8	24
125	Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I. Hematology American Society of Hematology Education Program, 2008, 2008, 186-192.	0.9	22
126	Expression of Regulatory Platelet MicroRNAs in Patients with Sickle Cell Disease. PLoS ONE, 2013, 8, e60932.	1.1	21

#	Article	IF	Citations
127	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances, 2019, 3, 4002-4020.	2.5	21
128	The proteome of sickle cell disease: insights from exploratory proteomic profiling. Expert Review of Proteomics, 2010, 7, 833-848.	1.3	20
129	Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. Haematologica, 2010, 95, 1467-1472.	1.7	19
130	High-Density Lipoprotein Cholesterol Efflux, Nitration of Apolipoprotein A-I, and Endothelial Function in Obese Women. American Journal of Cardiology, 2012, 109, 527-532.	0.7	19
131	Lactate dehydrogenase and hemolysis in sickle cell disease. Blood, 2013, 122, 1091-1092.	0.6	19
132	Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The <scp>PUSH</scp> study. American Journal of Hematology, 2020, 95, 766-774.	2.0	19
133	Hydroxyurea Utilization in Nigeria, a Lesson in Public Health.. Blood, 2007, 110, 80-80.	0.6	19
134	A Phase 1, First-in-Man, Dose-Response Study of Aes-103 (5-HMF), an Anti-Sickling, Allosteric Modifier of Hemoglobin Oxygen Affinity in Healthy Norman Volunteers. Blood, 2012, 120, 3210-3210.	0.6	19
135	The mUBC9 murine ubiquitin conjugating enzyme interacts with the E2A transcription factors. Gene, 1997, 201, 169-177.	1.0	18
136	Strategic Plan for Pediatric Respiratory Diseases Research: An NHLBI Working Group Report. Proceedings of the American Thoracic Society, 2009, 6, 1-10.	3.5	18
137	Predictors of osteoclast activity in patients with sickle cell disease. Haematologica, 2011, 96, 1092-1098.	1.7	18
138	Skeletal and myocardial microvascular blood flow in hydroxycarbamideâ€treated patients with sickle cell disease. British Journal of Haematology, 2017, 179, 648-656.	1.2	18
139	Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia. Blood, 2013, 122, 1009-1009.	0.6	18
140	Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. Haematologica, 2012, 97, 1768-1770.	1.7	17
141	Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease. Microvascular Research, 2012, 84, 262-269.	1.1	17
142	Heme Induces IL-6 and Cardiac Hypertrophy Genes Transcripts in Sickle Cell Mice. Frontiers in Immunology, 2020, 11, 1910.	2.2	17
143	A fluorescence method to detect and quantitate sterol esterification by lecithin:cholesterol acyltransferase. Analytical Biochemistry, 2013, 441, 80-86.	1.1	16
144	Abstract Animations for the Communication and Assessment of Pain in Adults: Cross-Sectional Feasibility Study. Journal of Medical Internet Research, 2018, 20, e10056.	2.1	16

#	Article	IF	Citations
145	Prostacyclin-analog therapy in sickle cell pulmonary hypertension. Haematologica, 2017, 102, e163-e165.	1.7	15
146	Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. Journal of Clinical Medicine, 2022, 11, 630.	1.0	15
147	Effects of a Single Sickling Event on the Mechanical Fragility of Sickle Cell Trait Erythrocytes. Hemoglobin, 2010, 34, 24-36.	0.4	14
148	Reconstruction of thermographic signals to map perforator vessels in humans. Quantitative InfraRed Thermography Journal, 2012, 9, 123-133.	2.1	14
149	TRV: A physiological biomarker in sickle cell disease. Pediatric Blood and Cancer, 2012, 58, 831-832.	0.8	14
150	Liver stiffness increases acutely during sickle cell vasoâ€•occlusive crisis. American Journal of Hematology, 2013, 88, E250-4.	2.0	14
151	Free heme regulates placenta growth factor through NRF2-antioxidant response signaling. Free Radical Biology and Medicine, 2019, 143, 300-308.	1.3	14
152	Microvascular oxygen consumption during sickle cell pain crisis. Blood, 2014, 123, 3101-3104.	0.6	13
153	Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy.. Blood, 2004, 104, 235-235.	0.6	13
154	Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.. Blood, 2009, 114, 571-571.	0.6	13
155	Strategic plan for pediatric respiratory diseases research: An NHLBI working group report. Pediatric Pulmonology, 2009, 44, 2-13.	1.0	12
156	Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease. Hepatology, 2020, 72, 2165-2181.	3.6	12
157	Defective nitric oxide metabolism in sickle cell disease. Pediatric Blood and Cancer, 2015, 62, 373-374.	0.8	11
158	Sleep phenotype in the Townes mouse model of sickle cell disease. Sleep and Breathing, 2019, 23, 333-339.	0.9	11
159	Sickle Cell Imaging Flow Cytometry Assay (SIFCA). Methods in Molecular Biology, 2016, 1389, 279-292.	0.4	11
160	Vascular complications after splenectomy for hematologic disorders. Blood, 2009, 114, 5404-5404.	0.6	10
161	Effect of Extended-Release Niacin on Serum Lipids and on Endothelial Function in Adults With Sickle Cell Anemia and Low High-Density Lipoprotein Cholesterol Levels. American Journal of Cardiology, 2013, 112, 1499-1504.	0.7	10
162	Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease. Haematologica, 2016, 101, e40-e43.	1.7	10

#	Article	IF	Citations
163	Thrombospondinâ€1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. American Journal of Hematology, 2017, 92, E31-E34.	2.0	10
164	DNA binding by the Myc oncoproteins. Cancer Treatment and Research, 1993, 63, 313-325.	0.2	10
165	Mechanisms and Clinical Complications of Hemolysis in Sickle Cell Disease and Thalassemia. , 2009, , 201-224.		9
166	NTâ€proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. British Journal of Haematology, 2010, 150, 102-107.	1.2	9
167	No NO means yes to sickle red cell adhesion. Blood, 2014, 123, 1780-1782.	0.6	8
168	Nrf2 deficiency in mice attenuates erythropoietic stress-related macrophage hypercellularity. Experimental Hematology, 2020, 84, 19-28.e4.	0.2	8
169	The CYB5R3 c . 350C >G and G6PD A alleles modify severity of anemia in malaria and sickle cell disease. American Journal of Hematology, 2020, 95, 1269-1279.	2.0	8
170	Computed Tomography Correlates with Cardiopulmonary Hemodynamics in Pulmonary Hypertension in Adults with Sickle Cell Disease. Pulmonary Circulation, 2014, 4, 319-329.	0.8	7
171	Iron restriction in sickle cell anemia: Time for controlled clinical studies. American Journal of Hematology, 2015, 90, E217.	2.0	7
172	Rapid vs. delayed infrared responses after ischemia reveal recruitment of different vascular beds. Quantitative InfraRed Thermography Journal, 2015, 12, 173-183.	2.1	7
173	Haem augments and iron chelation decreases tollâ€like receptor 4 mediated inflammation in monocytes from sickle cell patients. British Journal of Haematology, 2018, 181, 552-554.	1.2	7
174	Sickle cells and sickle trait in thrombosis. Blood, 2019, 133, 2463-2463.	0.6	7
175	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. Blood, 2006, 108, 1208-1208.	0.6	7
176	Antiâ€haemolytic effect of senicapoc and decrease in NTâ€proBNP in adults with sickle cell anaemia. British Journal of Haematology, 2011, 155, 634-636.	1.2	6
177	Imaging flow cytometry documents incomplete resistance of human sickle F-cells to ex vivo hypoxia-induced sickling. Blood, 2014, 124, 658-660.	0.6	6
178	Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. British Journal of Haematology, 2015, 168, 737-746.	1.2	6
179	Gout and sickle cell disease: not all pain is sickle cell pain. British Journal of Haematology, 2015, 171, 872-875.	1.2	6
180	Cardiac expression of HMOX1 and PGF in sickle cell mice and haemâ€treated wild type mice dominates organ expression profiles via Nrf2 (Nfe2l2). British Journal of Haematology, 2019, 187, 666-675.	1.2	6

#	Article	IF	Citations
181	Gene Therapy as the New Frontier for Sickle Cell Disease. Current Medicinal Chemistry, 2022, 29, 453-466.	1.2	6
182	NT-Pro Brain Natriuretic Peptide Levels and the Risk of Stroke and Death in the Cooperative Study of Sickle Cell Disease.. Blood, 2009, 114, 1541-1541.	0.6	6
183	Thrombin Generation in Sickle Cell Disease: Insights From Computerized Automated Thrombography.. Blood, 2009, 114, 2587-2587.	0.6	6
184	Clinical and Genetic Variability of Red Blood Cell Hemolysis in Sickle Cell Anemia. Blood, 2011, 118, 1077-1077.	0.6	6
185	Iron deficiency decreases hemolysis in sickle cell anemia. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 51-53.	0.7	6
186	Childhood Hodgkin and Non-Hodgkin Lymphomas. Pediatrics in Review, 1990, 12, 171-179.	0.2	5
187	Severe pulmonary hypertension in an adolescent with sickle cell disease. American Journal of Hematology, 2008, 83, 71-72.	2.0	5
188	Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease. Blood, 2012, 119, 5671-5673.	0.6	5
189	A GCH1 Haplotype Associated with Susceptibility to Vasoocclusive Pain and Impaired Vascular Function in Sickle Cell Anemia.. Blood, 2009, 114, 575-575.	0.6	5
190	Management of Patients With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2015, 313, 91.	3.8	4
191	Sickle cell vasculopathy: vascular phenotype on fire!. Journal of Physiology, 2019, 597, 993-994.	1.3	4
192	Inflammation and Sickle Cell Anemia. , 2016, , 177-211.		4
193	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease.. Blood, 2005, 106, 206-206.	0.6	4
194	The Hyperhemolysis Phenotype in Sickle Cell Anemia: Increased Risk of Leg Ulcers, Priapism, Pulmonary Hypertension and Death with Decreased Risk of Vasoocclusive Events.. Blood, 2006, 108, 787-787.	0.6	4
195	The Anti-Sickling Agent Aes-103 Decreases Sickle Erythrocyte Fragility, Hypoxia-Induced Sickling and Hemolysis In Vitro. Blood, 2013, 122, 940-940.	0.6	4
196	Immunomodulatory actions of a kynurenine-derived endogenous electrophile. Science Advances, 2022, 8, .	4.7	4
197	Pulmonary Complications of Sickle Cell Disease. New England Journal of Medicine, 2009, 360, 1044-1045.	13.9	3
198	Evaluation Of Sildenafil Therapy For Patients With Sickle Cell Disease And Increased Tricuspid Regurgitant Velocity: Preliminary Results Of The Walk-PHaSST Trial. , 2010, , .		3

#	Article	IF	Citations
199	Characterizing non-linear dependencies among pairs of clinical variables and imaging data. , 2012, 2012, 2700-3.		3
200	Understanding the Erythrocyte Storage Lesion. Anesthesiology, 2012, 117, 1159-1161.	1.3	3
201	Brief topical sodium nitrite and its impact on the quality of life in patients with sickle leg ulcers. Medicine (United States), 2018, 97, e12614.	0.4	3
202	Validation of a composite vascular highâ€risk profile for adult patients with sickle cell disease. American Journal of Hematology, 2019, 94, E312-E314.	2.0	3
203	Health-related quality of life in sickle cell disease. Nature Reviews Disease Primers, 2019, 5, 27.	18.1	3
204	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts. PLoS ONE, 2020, 15, e0237543.	1.1	3
205	Risk Factors for Echocardiography-Determined Cardiopulmonary Abnormalities In Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 260-260.	0.6	3
206	Hemodynamic Parameters Predict Mortality In Sickle Cell Disease-Related Pulmonary Hypertension. Blood, 2010, 116, 2668-2668.	0.6	3
207	Neutrophil-Platelet Aggregation Enables Vaso-Occlusion in Sickle Cell Disease. Blood, 2016, 128, 1295-1295.	0.6	3
208	The Impact of Cognitive Function on Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease. Blood, 2016, 128, 2493-2493.	0.6	3
209	Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia". Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 405-406.	0.7	3
210	Platelet Activation Is Linked to the Severity of Pulmonary Hypertension in Sickle Cell Disease and Normalizes on Sildenafil Therapy.. Blood, 2005, 106, 3166-3166.	0.6	3
211	Low-dose methotrexate therapy for hepatoblastoma. Cancer Chemotherapy and Pharmacology, 1991, 28, 233-234.	1.1	2
212	A novel defense against hemolytic-oxidative stress. Blood, 2006, 108, 2504-2505.	0.6	2
213	Homozygous factorâ€V mutation as a genetic cause of perinatal thrombosis and cerebral palsy. Developmental Medicine and Child Neurology, 1999, 41, 777-780.	1.1	2
214	Anemia, age, desaturation, and impaired neurocognition in sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 773-774.	0.8	2
215	Circulating Endothelial Progenitor Cells in Adults with Sickle Cell Disease. Pulmonary Circulation, 2013, 3, 448-449.	0.8	2
216	The Role of Platelets in Sickle Cell Disease. , 2019, , 563-580.		2

#	Article	IF	Citations
217	Anakinra, What Is Thy Bidding in Pulmonary Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 267-269.	2.5	2
218	Identifying adolescent and young adult patients with sickle cell disease at highest risk of death. American Journal of Hematology, 2021, 96, 9-11.	2.0	2
219	Plasma Level of NT-Pro-BNP In Children with Sickle Cell Disease Is Associated with Degree of Anemia and Left Ventricular Measures: The PUSH Study. Blood, 2010, 116, 948-948.	0.6	2
220	Quantification of Anti-Sickling Effect of Aes-103 in Sickle Cell Disease Using an in Vitro Microfluidic Assay. Blood, 2014, 124, 2699-2699.	0.6	2
221	Stimulation of Nitric Oxide Synthase Activity By Plasma Apolipoproteins: a Biomarker of Endothelial Function in Adults with Sickle Cell Disease. Blood, 2014, 124, 4015-4015.	0.6	2
222	Exerciseâ€induced changes of vital signs in adults with sickle cell disease. American Journal of Hematology, 2021, 96, 1630-1638.	2.0	2
223	Prospective Evaluation of the Prevalence of Elevated Tricuspid Regurgitant Jet Velocity and Associated Clinical and Echocardiographic Factors in Children and Adolescents with Sickle Cell Disease.. Blood, 2007, 110, 3388-3388.	0.6	2
224	Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model. American Journal of Physiology - Cell Physiology, 2022, 323, C494-C504.	2.1	2
225	Tumor Pseudosyncytiae. New England Journal of Medicine, 2003, 348, 1348-1348.	13.9	1
226	Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell Diseaseâ€”Reply. JAMA - Journal of the American Medical Association, 2005, 294, 2432.	3.8	1
227	Non-invasive indicators of pulmonary hypertension from pulmonary veins quantification in sickle cell disease. , 2012, , .		1
228	Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 238-240.	2.5	1
229	Exercise training: a prescription for sickle-cell disease?. Lancet Haematology,the, 2018, 5, e502-e503.	2.2	1
230	Sickle particulars of microparticles. Blood, 2020, 136, 154-155.	0.6	1
231	Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease. American Journal of Hematology, 2021, 96, E315-E318.	2.0	1
232	A Phase II Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers. Blood, 2019, 134, 2292-2292.	0.6	1
233	Genetic Polymorphisms in NEDD4L Are Associated with Pulmonary Hypertension of Sickle Cell Anemia.. Blood, 2009, 114, 2562-2562.	0.6	1
234	Cytochrome b5 Reductase T116S Mutation and Hemolysis in Sickle Cell Disease.. Blood, 2009, 114, 903-903.	0.6	1

#	Article	IF	Citations
235	Health Care Utilization for Painful Events Is Associated with Early Mortality in a Contemporary Population of Adults with Sickle Cell Anemia. Blood, 2011, 118, 2115-2115.	0.6	1
236	Predictors of Mortality in Children and Adolescents with Sickle Cell Disease: The PUSH Study. Blood, 2011, 118, 515-515.	0.6	1
237	Imaging Flow Cytometry for Fully Automated Quantification of Percentage of Sickled Cells in Sickle Cell Anemia.. Blood, 2012, 120, 2105-2105.	0.6	1
238	Effect of Aes-103 Anti-Sickling Agent On Oxygen Affinity and Stability of Red Blood Cells From Patients with Sickle Cell Anemia. Blood, 2012, 120, 85-85.	0.6	1
239	Sickle Cell Leg Ulcers Are Associated with Hyperuricemia, Hemolysis, Pulmonary Hypertension and Death.. Blood, 2009, 114, 2583-2583.	0.6	1
240	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 947-947.	0.6	1
241	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. Blood, 2011, 118, 1074-1074.	0.6	1
242	A Phase 1, Dose-Escalation Study of Topical Sodium Nitrite in Patients with Sickle Cell Anemia and Leg Ulcers. Blood, 2012, 120, 86-86.	0.6	1
243	Blood Flow Is Increased in Wounds and Peri-Wound Area by Laser Speckle Contrast Imaging and Infrared Thermography in Adults with Sickle Cell Leg Ulcers. Blood, 2012, 120, 1009-1009.	0.6	1
244	Imaging Flow Cytometry and Microfluidic Flow Assays Demonstrate Heterocellular Aggregation Of Immature Sickle Erythrocytes To Neutrophils Via Mac-1/VLA-4 Interactions. Blood, 2013, 122, 318-318.	0.6	1
245	Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. Journal of Clinical Investigation, 2014, 124, 3274-3274.	3.9	1
246	Iron, Expression of the Pattern Recognition Receptor-Inflammasome System, and Early Death in Adults with Sickle Cell Disease. Blood, 2014, 124, 2702-2702.	0.6	1
247	Higher Myocardial and Skeletal Muscle Microvascular Flow in Sickle Cell Disease Patients on Hydroxyurea. Blood, 2016, 128, 1020-1020.	0.6	1
248	Hairy Platelet-Derived Extracellular Vesicles Promote Lung Vaso-Occlusion in Sickle Cell Disease. Blood, 2017, 130, 958-958.	0.6	1
249	Impaired Bile Secretion Promotes Chronic Liver Injury in Sickle Cell Disease. Blood, 2019, 134, 3536-3536.	0.6	1
250	Exercise Induced Changes of Vital Signs in Adults with Sickle Cell Disease. Blood, 2020, 136, 59-60.	0.6	1
251	Safety of liver biopsy in patients with sickle cell related liver disease: A singleâ€center experience. American Journal of Hematology, 2022, 97, .	2.0	1
252	Review of Five therapists and one client.. Psychotherapy, 1992, 29, 686-687.	0.7	0

#	Article	IF	Citations
253	Longitudinal Change In Pulmonary Function In Children With Sickle Cell Disease And Associated Factors. , 2010, , .		0
254	Study Of Clinical Characteristics Of Sickle Cell Disease Patients Developing Cor-Pulmonale During Acute Hospitalization. , 2011, , .		0
255	Pulmonary Function In Adults With Sickle Cell Related Pulmonary Hypertension. , 2011, , .		0
256	Abnormal Methacholine Challenge Associated With Pulmonary Arterial Hypertension In Adults With Sickle Cell Disease. , 2011, , .		0
257	An Elevated Tricuspid Regurgitant Jet Velocity In Sickle Cell Disease Is Associated With Polymorphisms In Genes Impacting Innate Immunity. , 2012, , .		0
258	Computer-assisted diagnostic tool to quantify the pulmonary veins in sickle cell associated pulmonary hypertension. Proceedings of SPIE, 2012, , .	0.8	0
259	RV dysfunction by MRI is associated with elevated transpulmonary gradient and poor prognosis in patients with sickle cell associated pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2013, 15, O43.	1.6	0
260	Mo1001 Nodular Regenerative Hyperplasia: Many Ways to Get There. Gastroenterology, 2014, 146, S-983.	0.6	0
261	The Defective Arginine-Nitric Oxide Pathway in Sickle Cell Disease. , 2017, , 355-371.		0
262	Sickle related events following cardiac catheterisation: risk implication for other invasive procedures. British Journal of Haematology, 2019, 185, 778-780.	1.2	0
263	Kynurenine-derived Electrophiles: Potential Adaptive Mediators in Sickle Cell Disease. Free Radical Biology and Medicine, 2020, 159, S35-S36.	1.3	0
264	147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN). Journal of Sexual Medicine, 2020, 17, S43.	0.3	0
265	Proteomic Identification of Dysregulated Apolipoprotein Expression in Pulmonary Hypertension Secondary to Sickle Cell Disease.. Blood, 2005, 106, 3168-3168.	0.6	0
266	Mutations and Polymorphisms Influencing Hemolysis in Hemoglobin Genes and Risk of Pulmonary Hypertension in Sickle Cell Disease: Effect of Hemoglobin SC.. Blood, 2006, 108, 1206-1206.	0.6	0
267	Arginine Metabolite Profiling in Sickle Cell Disease: Abnormal Levels and Correlations with Pulmonary Hypertension, Desaturation, Hemolysis and Organ Dysfunction.. Blood, 2006, 108, 1205-1205.	0.6	0
268	Amplified Expression Profiling of Platelet Transcriptome Reveals Global Activation of Arginine Metabolic Pathways in Patients with Sickle Cell Disease.. Blood, 2006, 108, 1536-1536.	0.6	0
269	Detection of the mRNA Transcription Level of Several Genes of the HIF and NO Metabolic Pathways in PBMCs of Sickle Cell Disease Patients Using Quantitative RT-PCR Assay.. Blood, 2007, 110, 844-844.	0.6	0
270	Phosphodiesterase Inhibition Increases Fetal Hemoglobin in Sickle Cell Disease; L-Arginine Supplementation Does Not.. Blood, 2007, 110, 3396-3396.	0.6	0

#	Article	IF	Citations
271	Association of Hemolysis with Clinical Manifestations of Sickle Cell Disease. Blood, 2008, 112, 2482-2482.	0.6	0
272	Lower Ferritin Concentrations in Children with Sickle Cell Disease Are Associated with Decreased Hemolysis and Lower Tricuspid Regurgitant Velocity. Blood, 2008, 112, 4810-4810.	0.6	0
273	Oxygen Desaturation at Rest and after Exercise in Pediatric Sickle Cell Disease Patients: Correlations with Hemolysis and Elevated Tricuspid Regurgitant Jet Velocity.. Blood, 2008, 112, 1423-1423.	0.6	0
274	Placental Growth Factor Is Elevated in Patients with Sickle Cell Disease and Associated with Pulmonary Hypertension, Hemolysis, Inflammation, Iron Overload, and Hepatic Dysfunction.. Blood, 2009, 114, 1531-1531.	0.6	0
275	Lower Ferritin Concentrations Are Associated with Decreased Hemolysis in Sickle Cell Disease Children without Iron Overload.. Blood, 2009, 114, 2571-2571.	0.6	0
276	Hemolysis-Associated Elevation in Tricuspid Regurgitation Velocity Predicts Reduction in Six-Minute Walk Distance After Two Years of Follow up in Children and Adolescents with Sickle Cell Disease.. Blood, 2009, 114, 574-574.	0.6	0
277	Association of G6PD â˜’202/â˜’376 with Lower Hemoglobin Concentration but Not Increased Hemolysis in Patients with Sickle Cell Anemia.. Blood, 2009, 114, 1511-1511.	0.6	0
278	Plasma Thrombospondin 1 Is Increased and Associated with Markers of Vasculopathy In Sickle Cell Disease. Blood, 2010, 116, 946-946.	0.6	0
279	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 1639-1639.	0.6	0
280	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood, 2010, 116, 2658-2658.	0.6	0
281	Evaluation of Exercise Capacity In Children with SCD by Six Minute Walk Test. Blood, 2010, 116, 2664-2664.	0.6	0
282	Serum B12 Levels In Children with Sickle Cell Disease Are Lower Than In Healthy Control Subjects. Blood, 2010, 116, 1647-1647.	0.6	0
283	Sickle Cell Disease-Associated Pulmonary Hypertension: The Effect of Anemia and High Cardiac Output. International Journal of Clinical Reviews, 0, , .	0.1	0
284	Serum Transferrin: An Independent Predictor of Mortality in Sickle Cell Anemia. Blood, 2011, 118, 2126-2126.	0.6	0
285	A Cell-Based Adhesion Molecule Bioassay Detects Unexpected Properties of Plasma From Patients with Sickle Cell Disease with Documented Pulmonary Hypertension. Blood, 2011, 118, 2120-2120.	0.6	0
286	Iron Containing Compound Stimulates Expression of Pulmonary Hypertension Promoting Factor PlGF. Blood, 2011, 118, 900-900.	0.6	0
287	Integration of Genomic and Genetic Approaches Highlight a Novel Validated Gene Signature for Pulmonary Hypertension Associated with Sickle Cell Disease. Blood, 2011, 118, 511-511.	0.6	0
288	Increased Transpulmonary Gradient Predicts Functional Class, Mortality, and RV Dysfunction by MRI in Patients with Sickle Cell Associated Pulmonary Hypertension. Blood, 2012, 120, 89-89.	0.6	0

#	Article	IF	Citations
289	Turnover of Heme-Bound Iron Is Associated with Activation of TLR4 and Chemokine Receptor Pathways in the Peripheral Blood Mononuclear Cell Transcriptome in Sickle Cell Anemia. Blood, 2012, 120, 819-819.	0.6	0
290	Laser Speckle Contrast Imaging Characterizes Delayed Reperfusion After Transient Brachial Artery Occlusion in Patients with Sickle Cell Diseas. Blood, 2012, 120, 1080-1080.	0.6	0
291	Genetic Determinants of Hemolysis in Sickle Cell Anemia.. Blood, 2012, 120, 2104-2104.	0.6	0
292	Topical Sodium Nitrite Is Effective In Reducing Leg Ulcer-Associated Pain In Patients With Sickle Cell Disease. Blood, 2013, 122, 2236-2236.	0.6	0
293	Placenta Growth Factor Is Regulated By Heme-Bound Iron Via Erythroid KrÃ¼ppel-Like Factor In Erythroid Cells and Is Linked To Iron Status In Vivo In Sickle Cell Disease and Hereditary Hemochromatosis. Blood, 2013, 122, 432-432.	0.6	0
294	Imaging Flow Cytometry Documents Incomplete Resistance Of F-Cells To Hypoxia-Induced Sickling In Blood Samples From Patients With Sickle Cell Anemia. Blood, 2013, 122, 183-183.	0.6	0
295	End-Alveolar Carbon Monoxide As a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease. Blood, 2014, 124, 2696-2696.	0.6	0
296	Cardiopulmonary Functional Status in Children with SCD at Baseline: Pulse Pressure As a Biomarker of Early Compromise. Blood, 2014, 124, 2663-2663.	0.6	0
297	Elevated Pulse Pressure Is Associated with Hemolysis, Proteinuria and Chronic Kidney Disease in Sickle Cell Disease. Blood, 2014, 124, 2711-2711.	0.6	0
298	Association of FOXO3A Polymorphisms with Hematocrit, LDH and Longevity in Patients with Sickle Cell Anemia from CSSCD, Walk-Phasst, and PUSH Clinical Trials. Blood, 2015, 126, 2176-2176.	0.6	0
299	Thrombospondin-1 Gene Polymorphism Is Associated with Estimated Pulmonary Artery Pressure in Patients with Sickle Cell Anemia. Blood, 2015, 126, 970-970.	0.6	0
300	Platelet Nucleation on Arrested Neutrophils Drives Vaso-Occlusion in Sickle Cell Disease. Blood, 2015, 126, 414-414.	0.6	0
301	Heme Augments Toll-like Receptor 4 Signalling in Sickle Cell and Healthy Control Monocytes. Blood, 2015, 126, 2167-2167.	0.6	0
302	The Oxidant Response Transcription Factor NRF2 Mediates Heme Activation of Placenta Growth Factor Expression in Erythroid Cells, a Contributor to Pulmonary Hypertension in Sickle Cell Disease. Blood, 2015, 126, 403-403.	0.6	0
303	Biophysical markers of Sickle Cell Disease at Individual Cell Level. , 2016, , .		0
304	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Blood, 2016, 128, 2474-2474.	0.6	0
305	Hospitalization for Acute Pain in Sickle Cell Disease: Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission. Blood, 2016, 128, 3662-3662.	0.6	0
306	Amerindian/Asian Ancestry and Mortality Are Associated with Allo-Immunization in Adults with Sickle Cell Disease in a Genome Wide Racial Admixture Study. Blood, 2016, 128, 3650-3650.	0.6	0

#	Article	IF	Citations
307	Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia. Blood, 2016, 128, 2491-2491.	0.6	0
308	Cellular biophysical markers of hydroxyurea treatment in sickle cell disease. , 2017, , .		0
309	Clinical and Laboratory Predictors of 30-Day Hospital Readmission Risk in Adult Patients with Sickle Cell Disease. Blood, 2018, 132, 2384-2384.	0.6	0
310	Assessment of Iron Overload Impact on QTc Interval in Patients with Sickle Cell Disease. Blood, 2018, 132, 3673-3673.	0.6	0
311	Heterogeneity in Multi-Organ Expression of HO-1 and PlGF in Sickle Mice Mimic Exposure of Non-Sickle Mice to Extracellular Heme Via Nrf2-Dependent Pathways. Blood, 2018, 132, 2392-2392.	0.6	0
312	A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN). Blood, 2019, 134, 1007-1007.	0.6	0
313	360o View of a Day Hospital Program Performing Exchange Transfusion and Outpatient Pain Management on Adults with Sickle Cell Disease. Blood, 2019, 134, 5873-5873.	0.6	0
314	Sickle Cell Disease Promotes Dysregulation of Hepatic Iron Homeostasis By Regulating Hepcidin Expression. Blood, 2019, 134, 958-958.	0.6	0
315	Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease. Blood, 2019, 134, 2274-2274.	0.6	0
316	Macrophage Hypercellularity Accompanies Erythroid Hyperplasia in Sickle Cell Mice and during Recovery from Blood Loss in Wild Type Mice. Blood, 2019, 134, 3528-3528.	0.6	0
317	Nrf2 Null Mice Are Deficient in CD169+ Macrophages, Associated with Impaired Erythroid Response and Delayed Recovery from Acute Blood Loss. Blood, 2019, 134, 1038-1038.	0.6	0
318	Targeted Proteomics of Pulmonary Hypertension in Sickle Cell Disease. Blood, 2021, 138, 981-981.	0.6	0
319	Microvascular Stasis Inhibition By Hemopexin in the Townes Mouse Model of Sickle Cell Disease. Blood, 2020, 136, 9-9.	0.6	0
320	Prevention of Heme-Induced Human Endothelial Cell Activation By Hemopexin in Vitro. Blood, 2020, 136, 8-8.	0.6	0
321	Title is missing!. , 2020, 15, e0237543.		0
322	Title is missing!. , 2020, 15, e0237543.		0
323	Title is missing!. , 2020, 15, e0237543.		0
324	Title is missing!. , 2020, 15, e0237543.		0

#	Article	IF	Citations
325	Title is missing!. , 2020, 15, e0237543.		0
326	Title is missing!. , 2020, 15, e0237543.		0